Navigation Links
The Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
Date:11/13/2013

WHITE PLAINS, N.Y., Nov. 13, 2013 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of ibrutinib to treat patients with mantle cell lymphoma (MCL) is a significant advance for patients with this blood cancer.  It was approved as a single agent for treatment of patients with MCL who have received at least one prior therapy.

Ibrutinib is the second drug with "breakthrough therapy designation" to receive FDA approval. Ibrutinib is a therapy that  targets an enzyme, Bruton's tyrosine kinase (BTK), which promotes growth of  B-cell cancers, including MCL, chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), follicular lymphoma, diffuse large B-cell lymphoma, hairy cell leukemia (HCL) and multiple myeloma.

"After the FDA earlier this year designated ibrutinib as a breakthrough therapy for patients with certain forms of blood cancers, we were all hopeful that it was only a matter of time before the therapy was approved to treat these patients, who have few good treatment options," said John Walter, president and CEO of The Leukemia & Lymphoma Society (LLS).

LLS is eager to learn the outcome of FDA's ongoing review of ibrutinib for patients with chronic lymphocytic leukemia (CLL) and Waldenstrom's macroglobulinemia (WM).

"Many patients with MCL and other B-cell cancers do not respond well to standard therapies and new treatments such as ibrutinib are urgently needed," said Louis J. DeGennaro, Ph.D., LLS chief mission officer.  "LLS exists to find cures and ensure access to treatments for blood cancer patients, and any new advance that brings the potential to help save more lives is good news."

LLS funding has supported clinical trials and laboratory studies of ibrutinib for patients with CLL, and more recently for patients with HCL. John C. Byrd, M.D., of the Ohio State University, is a world-renowned CLL expert who leads an LLS-funded research team that has been instrumental in advancing ibrutinib. Other LLS-funded researchers, including Jonathan Friedberg, M.D., of University of Rochester and Jennifer Brown, M.D., Ph.D., of Dana-Farber Cancer Institute, have also played important roles in clinical trials for ibrutinib.

LLS also helped advance another BTK inhibitor, CC-292 (formerly AVL-292), which showed encouraging activity in an early trial for CLL and lymphoma patients, and is now being tested in combination therapies. LLS partnered with Avila Therapeutics through LLS's Therapy Acceleration Program, from March 2010 until Celgene Corporation acquired Avila in January 2012, bringing critical capital and commercialization expertise to the development of this promising agent.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds livesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access o quality, affordable, coordinated care.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
914-821-8958
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
2. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
3. The Leukemia & Lymphoma Society Issues Statement Regarding the Status of Iclusig (Ponatinib)
4. The Leukemia & Lymphoma Society and the Knight Cancer Institute Launch Groundbreaking Collaboration to Improve Outcomes for Acute Myeloid Leukemia Patients
5. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
6. St. Jude Childrens Research Hospital study yields new strategy against high-risk leukemia
7. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
8. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
9. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
11. The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/10/2017)... June 9, 2017  Shane K. Burchfield, DPM, is recognized by ... as a Podiatrist in Alabama . ... First Foot Care. He brings over 20 years of experience, as ... and healthcare, to his role. ... PC is pleased to welcome you to his practice," ...
(Date:6/8/2017)... 8, 2017  Less than a month ago, amateur ... 200,000 companies, including hospital networks, in over 150 countries. ... of the largest online extortion attempts ever recorded. With ... it is imperative that providers understand where the risks ... this — and many other very real cyber threats.  ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest mortality rate of ... one person dies as a direct result from an eating disorder in the U.S. ... providers. The iaedp Foundation meets this challenge by offering what has become the leading ...
(Date:6/28/2017)... ... June 28, 2017 , ... Park Systems , ... Luncheon for all SEMICONWest attendees and Park customers on July 11, 2017 ... from Dr. Sang-il Park, Chairman & CEO of Park Systems, and Prof. Krishna ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... assistance and financial consultations to communities in northern Virginia and DC, is announcing ... help provide for patients with Alzheimer’s and other disorders that lead to memory ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Building on the success of the ... sixth state to pass legislation which ensures that children can possess and use ... the states of Alabama, Arizona, Florida, Utah and Washington who have also approved ...
Breaking Medicine News(10 mins):